Mustang Bio reports FY2022 net loss $77.5M; MB-106 shows 96% ORR, 75% CR

MUSTANG BIO, INC.

Cash and equivalents $76.7M at Dec 31, 2022, down from $110.6M year-over-year.
Net loss $77.5M ($0.75/share) vs $66.4M ($0.76/share) in 2021; R&D expenses rose to $62.5M.
MB-106 CAR T therapy achieved 96% ORR and 75% CR in hematologic malignancies; FDA Orphan Drug Designation for Waldenstrom macroglobulinemia.
Completed $75M debt financing with Runway Growth Capital; $30M funded at close, $45M milestone-based.
Plans to treat first pivotal Phase 2 WM patient in Q1 2024; additional data expected in Q2 and Q4 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MUSTANG BIO, INC. reported the full year ended December 31, 2022 results: net income Net loss attributable to common stockholders was $77.5 million, or $0.75 per share, for the year ended December 31, 2022, EPS $0.75 per share.

Period: the full year ended December 31, 2022
Net income: Net loss attributable to common stockholders was $77.5 million, or $0.75 per share, for the year ended December 31, 2022
EPS: $0.75 per share
Result: reported results

Exact text from the filing

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

View on SEC.gov

Browse all earnings releases →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-004930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.